After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar’s intranasal version
After coming under fire from angry lawmakers in the wake of its recent decision to more than double the price of its opioid intervention drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
